Coiled Therapeutics plc (COIL.L)
LSE · GBp · Healthcare · Biotechnology
£6.90 (-3.50%) as of
Key statistics
- Market cap
- 29.45M
- Forward P/E
- -7.34
- EPS (TTM)
- -0.20
- Dividend yield
- 0.00%
- 52-week range
- 0.95 – 30.00
- Profit margin
- 0.00%
- Analyst target
- £21.71
- Volume
- 200.00k
About Coiled Therapeutics plc
Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. The company's lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer. The company also offers a STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, and allergic disease, with plans for assessment towards Phase I clinical trials. The company is based in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- London, United Kingdom
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.